Pfizer announced the failure of its sickle cell drug candidate, inclacumab, in a pivotal Phase III clinical trial, where it did not demonstrate significant reduction in vaso-occlusive crises compared to placebo. This setback follows Pfizer's earlier withdrawal of Oxbryta amid safety concerns. The failure represents a notable challenge for Pfizer’s sickle cell portfolio, putting pressure on the company to re-evaluate its strategy in the sickle cell disease therapeutic area.